Michael Webb

Iqure Pharma, Inc. is a biotech company that develops therapeutics for patients and physicians. The company is based in Wilmington, DE. The company was founded by Pawel Zolnierczyk, Henk de Wilde, Peter Schiemann, Anna Rzewuska. Pawel Zolnierczyk has been the CEO since incorporation.

CXL Ophthalmics LLC develops a treatment for eyecare. The company is based in Encinitas, CA. The CEO of the company is Michael D. Webb.

Deuterx LLC engages in research of biotechnology. It also engages in development of biotechnology. The company was founded by Anthony W. Czarnik in 2012 and is headquartered in Andover, MA.

Allegro Diagnostics Corp. develops and commercializes molecular diagnostics system. It focuses on lung cancer and other pulmonary diseases using proprietary gene expression technology originating within the Pulmonary Center at the Boston University School of Medicine. The company was founded by Jerome S. Brody and Avrum Spira on April 20, 2007 and is headquartered in Maynard, MA.

EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA.

Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell.

Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA.

Tyrogenex, Inc. operates as a biopharmaceutical company which develops dual vascular endothelial growth factor receptor and platelet-derived growth factor receptor inhibitors for wet age-related macular degeneration and solid tumors. Its compound targets the basic mechanisms of neovascular eye diseases, including angiogenesis, fibrosis and inflammation. The company was founded by Chris Liang, Teri Ardleigh Swift, and Sheridan G. Snyder and is headquartered in Rockville, MD.